Efficacy News and Research

RSS
Genable Technologies, Spark Therapeutics to advance novel therapy for rare form of retinitis pigmentosa

Genable Technologies, Spark Therapeutics to advance novel therapy for rare form of retinitis pigmentosa

Diabetes drug reduces amyloid-beta peptides, improves memory in experimental AD models

Diabetes drug reduces amyloid-beta peptides, improves memory in experimental AD models

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Patrys provides update on development programme for anti-cancer product, PAT-LM1

Patrys provides update on development programme for anti-cancer product, PAT-LM1

FDA approves Xolair for treatment of chronic idiopathic urticaria

FDA approves Xolair for treatment of chronic idiopathic urticaria

Researchers developing new medication to tackle river blindness and elephantiasis

Researchers developing new medication to tackle river blindness and elephantiasis

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Biogen Idec's ALPROLIX gets Health Canada approval for hemophilia B

Tetraphase provides clinical update on lead antibiotic candidate and Phase 3 clinical program

Tetraphase provides clinical update on lead antibiotic candidate and Phase 3 clinical program

New treatment could halt progression of dementia

New treatment could halt progression of dementia

GHIT Fund announces grants to speed up innovative drug development for neglected diseases

GHIT Fund announces grants to speed up innovative drug development for neglected diseases

Adocia announces positive final results for first clinical trial of BioChaperone Combo

Adocia announces positive final results for first clinical trial of BioChaperone Combo

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

Emmaus reports preliminary top-line results from Phase 3 clinical trial for treatment of sickle cell disease

Emmaus reports preliminary top-line results from Phase 3 clinical trial for treatment of sickle cell disease

Novel method for evaluating treatment of obesity-related food behavior

Novel method for evaluating treatment of obesity-related food behavior

Real-time cervical cancer diagnostics: an interview with Sameer Kothari, Chief Executive of Zilico

Real-time cervical cancer diagnostics: an interview with Sameer Kothari, Chief Executive of Zilico

Novan Therapeutics reports positive results from SB204 Phase 2 study for treatment of acne vulgaris

Novan Therapeutics reports positive results from SB204 Phase 2 study for treatment of acne vulgaris

Ipsen: Dysport Phase IIa clinical trial effective in treatment of NDO

Ipsen: Dysport Phase IIa clinical trial effective in treatment of NDO

Dartmouth, Aeras to jointly conduct trial of DAR-901 vaccine against TB

Dartmouth, Aeras to jointly conduct trial of DAR-901 vaccine against TB

Amgen announces results from Phase 3 TESLA Trial of evolocumab in patients with HoFH

Amgen announces results from Phase 3 TESLA Trial of evolocumab in patients with HoFH

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.